Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Retained Earnings (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Retained Earnings for 13 consecutive years, with -$195000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 29.09% to -$195000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$195000.0 through Dec 2025, up 29.09% year-over-year, with the annual reading at -$195000.0 for FY2025, 29.09% up from the prior year.
  • Retained Earnings hit -$195000.0 in Q4 2025 for Coherus Oncology, up from -$203000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$195000.0 in Q4 2025 to a low of -$1.6 billion in Q1 2025.
  • Historically, Retained Earnings has averaged -$543.9 million across 5 years, with a median of -$275000.0 in 2024.
  • Biggest five-year swings in Retained Earnings: plummeted 1871502.0% in 2021 and later soared 99.99% in 2025.
  • Year by year, Retained Earnings stood at -$270000.0 in 2021, then plummeted by 496791.85% to -$1.3 billion in 2022, then dropped by 17.73% to -$1.6 billion in 2023, then surged by 99.98% to -$275000.0 in 2024, then rose by 29.09% to -$195000.0 in 2025.
  • Business Quant data shows Retained Earnings for CHRS at -$195000.0 in Q4 2025, -$203000.0 in Q3 2025, and -$275000.0 in Q2 2025.